GlassScriptPhysician profile
Jennifer A Kool
NPI 1700216108
$1,477.05
in general payments reported to CMS, 2019-2025
21 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $274 · 2023: $260 · 2024: $371 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $348.23 | 2021-2024 | Jardiance, Zepbound |
| Tandem Diabetes Care, INC. | $145.13 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $131.09 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $127.06 | 2025 | Omnipod |
| Dexcom, INC. | $107.91 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $106.94 | 2021-2024 | Evenity, Prolia, Repatha |
| Neurocrine Biosciences, INC. | $63.65 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $62.73 | 2023-2024 | |
| Novo Nordisk INC | $57.94 | 2023-2024 | Wegovy |
| Xeris Pharmaceuticals, INC. | $57.04 | 2022-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $46.93 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $43.32 | 2021-2022 | |
| Mannkind Corporation | $41.05 | 2023-2024 | Afrezza |
| Medtronic, INC. | $24.99 | 2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.88 | 2024 | Jardiance, Synjardy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $20.45 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $15.05 | 2025 | |
| Recordati_rare_diseases_inc. | $14.93 | 2021 | |
| Horizon Therapeutics Plc | $14.63 | 2023 | Tepezza |
| Cequr Corporation | $13.05 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.